跳转至内容
Merck
CN

1561507

USP

磷酸伯安喹

United States Pharmacopeia (USP) Reference Standard

别名:

8-(4-氨基-1-甲基丁氨基)-6-甲氧基喹啉 二磷酸盐, 伯氨喹 二磷酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H21N3O · 2H3PO4
CAS号:
分子量:
455.34
Beilstein:
3812133
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

primaquine

制造商/商品名称

USP

mp

205-206 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

OP(O)(O)=O.OP(O)(O)=O.COc1cc(NC(C)CCCN)c2ncccc2c1

InChI

1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

InChI key

GJOHLWZHWQUKAU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Primaquine phosphate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - Muta. 2 - Repr. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Salomón Durand et al.
The American journal of tropical medicine and hygiene, 91(1), 18-26 (2014-04-23)
We evaluated the efficacy of three primaquine (PQ) regimes to prevent relapses with Plasmodium vivax through an open-label randomized trial in Loreto, Peru. Vivax monoinfections were treated with chloroquine for 3 days and PQ in three different regimes: 0.5 mg/kg
Michael E von Fricken et al.
The American journal of tropical medicine and hygiene, 91(1), 77-80 (2014-04-30)
Administering primaquine (PQ) to treat malaria patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can pose a serious risk of drug-induced hemolysis (DIH). New easy to use point-of-care rapid diagnostic tests are being developed as an alternative to labor-intensive spectrophotometric methods, but
Low-dose primaquine for falciparum malaria.
Teun Bousema et al.
The Lancet. Infectious diseases, 14(8), 677-677 (2014-07-25)
Improving the radical cure of Plasmodium vivax malaria.
Ric N Price
The American journal of tropical medicine and hygiene, 91(1), 3-4 (2014-04-23)
Tamar E Carter et al.
The American journal of tropical medicine and hygiene, 91(2), 412-414 (2014-06-04)
Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门